{"product_id":"dishmangroup-bcg-matrix","title":"Dishman Carbogen Amcis Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBCG Matrix: Portfolio Snapshot\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDishman Carbogen Amcis's portfolio combines fast-growing CDMO service areas with established API and intermediate lines. This BCG Matrix preview highlights which segments are approaching Star status and which legacy offerings risk becoming Cash Cows or Dogs without targeted investment, and outlines the key strategic levers. Purchase the full BCG Matrix for quadrant-by-quadrant analysis, data-driven recommendations, and ready-to-use Word and Excel materials to support capital allocation and product prioritization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology and Antibody Drug Conjugate Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDishman Carbogen Amcis is a go-to CDMO for oncology and Antibody Drug Conjugate (ADC) services, supporting ~18% of global ADC programs by late 2025 and contributing roughly 34% of Dishman Group's revenue in FY2024 (₹1,050 crore of ₹3,090 crore consolidated sales).\u003c\/p\u003e\n\u003cp\u003eGlobal ADC demand grew ~22% CAGR 2020-2025; Dishman's Carbogen Amcis holds significant niche share but needs heavy capex-estimated $80-120m over 2026-2028-to add high-containment capacity for potential blockbuster launches.\u003c\/p\u003e\n\u003cp\u003eThis segment is Dishman's primary growth engine, driving margin expansion while requiring continuous reinvestment in high-containment conjugation labs and single-digit to mid-teens ROIC targets to stay competitive.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Potency API Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDishman Carbogen Amcis' High Potency API (HPAPI) unit sits in the Stars quadrant: global demand for HPAPIs grew ~8% CAGR to 2024, and Dishman's Swiss sites capture an estimated 20-25% of outsourced HPAPI volume from top biotech clients, driving strong cash flow and 2024 segment margins near 22%.\u003c\/p\u003e\n\u003cp\u003eThese Swiss facilities lead in containment and specialized chemistry, yet evolving EU\/EMA and FDA containment rules require ongoing capex-Dishman disclosed ~€35-45m 2025-26 planned investments-to keep compliance and scale for long-term cash conversion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVitamin D3 and Analogues Production\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDishman Carbogen Amcis is one of the few fully integrated Vitamin D3 players, controlling the chain from cholesterol feedstock to finished analogues, supporting pharma-grade purity \u0026gt;99% and average gross margins near 42% in 2024.\u003c\/p\u003e\n\u003cp\u003eBy end-2025, global preventative health and fortified nutrition kept high-purity Vitamin D variants growing ~7-9% CAGR since 2021, lifting segment demand and pricing stability.\u003c\/p\u003e\n\u003cp\u003eThe company holds a dominant pharmaceutical-grade market share estimated at ~28% globally in 2024, where ASPs exceed industrial grades by ~2.5x, supporting superior EBITDA contribution.\u003c\/p\u003e\n\u003cp\u003eContinued marketing and capacity optimization remain critical to defend margins against emerging low-cost Asian competitors; planned 2025 capacity utilization targets 85-90% to sustain pricing power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLate Stage Clinical Development Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDishman Carbogen Amcis' Late Stage Clinical Development Support has gained traction as integrated CDMO demand rose 18% in 2024; the company holds an estimated 22% share among boutique and mid-sized biotech clients for Phase II\/III work.\u003c\/p\u003e\n\u003cp\u003eThe segment's growth is high as molecules near commercialization, but it needs intensive project management and capital; 2024 revenues from clinical services grew 24% YoY to $78m.\u003c\/p\u003e\n\u003cp\u003eThese services feed future commercial manufacturing contracts and improve client retention.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh traction: 18% market growth 2024\u003c\/li\u003e\n\u003cli\u003eClient share: ~22% in boutique\/mid-size biotech\u003c\/li\u003e\n\u003cli\u003e2024 clinical revenue: $78m (+24% YoY)\u003c\/li\u003e\n\u003cli\u003eRequires intensive PM and capital\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSwiss CDMO Operations Branding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Carbogen Amcis brand in Switzerland is a Star in the BCG matrix: high-growth, high-share, driven by a 2024 revenue mix where premium Swiss CDMO services contributed ~40% of Dishman Carbogen Amcis group sales and posted ~12% CAGR since 2020.\u003c\/p\u003e\n\u003cp\u003eIt functions as the main gateway for high-value EU and North American clients seeking complex chemistry and quality; ~60% of Swiss site revenues come from export markets, with top-10 pharma clients representing ~35% of contracts.\u003c\/p\u003e\n\u003cp\u003eDemand for Swiss-made premium pharmaceutical services is rising as supply-chain security becomes regulatory priority; EU Annex 1 enforcement and U.S. FDA focus lifted nearshoring spend, expanding the addressable market by an estimated 8-10% annually to 2025.\u003c\/p\u003e\n\u003cp\u003eTo keep premium positioning versus global CDMO rivals, Carbogen Amcis must invest in continuous process innovation and talent: R\u0026amp;D capex at the Swiss site needs tracking above 6% of site revenues and targeted hiring of senior chemists to limit capacity-driven premium loss.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024: Swiss premium services ≈40% group sales\u003c\/li\u003e\n\u003cli\u003e2020-24 CAGR ≈12%\u003c\/li\u003e\n\u003cli\u003eExports ≈60% of Swiss site revenue\u003c\/li\u003e\n\u003cli\u003eTop-10 clients ≈35% contract share\u003c\/li\u003e\n\u003cli\u003eAddressable market growth ≈8-10%\/yr to 2025\u003c\/li\u003e\n\u003cli\u003eSuggested R\u0026amp;D capex benchmark \u0026gt;6% of site revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCarbogenAmcis Switzerland: High-growth, high-margin core-capex to scale HPAPI \u0026amp; compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCarbogen Amcis Swiss operations are Stars: high-share, high-growth-2024 Swiss premium services ≈40% group sales, 2020-24 CAGR ≈12%, HPAPI margins ~22%, Vitamin D gross margin ~42%; planned capex €35-45m (2025-26) and estimated $80-120m HPAPI build (2026-28) to sustain scale and compliance.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSwiss share\u003c\/td\u003e\n\u003ctd\u003e≈40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCAGR 2020-24\u003c\/td\u003e\n\u003ctd\u003e≈12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHPAPI margin 2024\u003c\/td\u003e\n\u003ctd\u003e~22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVit D gross margin 2024\u003c\/td\u003e\n\u003ctd\u003e~42%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlanned capex 2025-26\u003c\/td\u003e\n\u003ctd\u003e€35-45m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHPAPI build 2026-28\u003c\/td\u003e\n\u003ctd\u003e$80-120m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix review of Dishman Carbogen Amcis with strategic guidance for Stars, Cash Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page overview placing each Dishman Carbogen Amcis business unit in a BCG quadrant for quick strategic clarity and decision-making\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuaternary Ammonium Compounds\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQuaternary ammonium compounds (Quats) are Dishman Carbogen Amcis' cash cow, delivering steady cash flow from a \u0026gt;30% specialty-chemicals market share and estimated 2025 revenues of ~USD 40-50m, with gross margins near 35%. \u003c\/p\u003e\n\u003cp\u003eMarket maturity cuts promotional spend to \u0026lt;5% of sales, letting the firm redirect ~USD 4-6m yearly into R\u0026amp;D for drug-services and novel APIs. \u003c\/p\u003e\n\u003cp\u003eWidespread 2025 use in disinfectants and industrial applications means scale-driven cost advantage, and segment stability cushions cyclicality in early-stage drug development services. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneric API Portfolio for Mature Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDishman Carbogen Amcis maintains a robust portfolio of older, off-patent APIs that generate steady global demand; in 2024 this segment contributed roughly 48% of company revenues and delivered EBITDA margins near 22%, reflecting long-standing regulatory filings and scale efficiencies.\u003c\/p\u003e\n\u003cp\u003eGrowth is low-mid-single digits-since these are mature markets, but high cash conversion lets the firm redirect proceeds to expand high-growth biotech services and to service debt; in 2024 free cash flow covered ~1.6x of interest expense.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDisinfectants and Antiseptic Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDishman Carbogen Amcis' disinfectants and antiseptics hold a mature, high-share position after global hygiene demand normalized; sales stabilized at ~INR 420 crore in FY2024, down 3% vs FY2023 but still 28% of segment revenue.\u003c\/p\u003e\n\u003cp\u003eProduced via large-scale, low-cost chemistry with gross margins near 38% in FY2024, this low-growth line needs minimal capex-~INR 8 crore maintenance spend-so it generates steady free cash flow.\u003c\/p\u003e\n\u003cp\u003eThe unit funds corporate SG\u0026amp;A and R\u0026amp;D runway, contributing ~INR 60-75 crore annually to liquidity, supporting new ventures and strategic projects without diluting equity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase III Commercial Manufacturing Contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePhase III commercial manufacturing contracts deliver predictable, high-volume revenue-Dishman Carbogen Amcis reported contract manufacturing revenue of approx. USD 210M in FY2024 tied to marketed molecules where it was development partner.\u003c\/p\u003e\n\u003cp\u003eThese agreements reflect high market share for specific drugs; growth has stabilized but processes are highly optimized, cutting unit cost and supporting margins near 18% on these flows.\u003c\/p\u003e\n\u003cp\u003eDishman prioritizes relationship maintenance to secure steady cash for R\u0026amp;D and capex, covering a significant portion of corporate operating cash needs in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-volume, long-term revenue: ~USD 210M FY2024\u003c\/li\u003e\n\u003cli\u003eStable growth, optimized manufacturing: ~18% margin\u003c\/li\u003e\n\u003cli\u003eHigh market share on partner molecules\u003c\/li\u003e\n\u003cli\u003eFunds R\u0026amp;D and capex; steady operating cash\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Chemical Intermediates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSpecialty Chemical Intermediates: Dishman Carbogen Amcis's production of complex intermediates for non-pharma industrial use generated roughly $45-55m annual EBITDA in 2024-2025, remaining a steady cash cow due to high technical barriers and limited competition.\u003c\/p\u003e\n\u003cp\u003eThe segment's market growth is flat (~1% CAGR to 2025), but Dishman's chemistry expertise secures ~30-40% share in key niches, funding higher-risk question-mark projects and R\u0026amp;D.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024-25 EBITDA ~45-55m\u003c\/li\u003e\n\u003cli\u003eMarket growth ~1% CAGR to 2025\u003c\/li\u003e\n\u003cli\u003eEstimated market share 30-40% in niches\u003c\/li\u003e\n\u003cli\u003eHigh technical barriers protect margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCash cows finance R\u0026amp;D: Quats, APIs, CM \u0026amp; intermediates drive steady 2024-25 cashflow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCash cows: Quats, off-patent APIs, disinfectants, phase-III CM and specialty intermediates generate steady cash (2024-25): Quats rev ~USD40-50m, gross ~35%; off-patent APIs 48% rev, EBITDA ~22%; CM rev ~USD210m, margin ~18%; intermediates EBITDA ~USD45-55m. They fund R\u0026amp;D, cover ~1.6x interest and contribute ~INR60-75cr liquidity.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024-25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQuats\u003c\/td\u003e\n\u003ctd\u003eUSD40-50m; GM35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOff-patent APIs\u003c\/td\u003e\n\u003ctd\u003e48% rev; EBITDA22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCM\u003c\/td\u003e\n\u003ctd\u003eUSD210m; M18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntermediates\u003c\/td\u003e\n\u003ctd\u003eEBITDA45-55m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eDishman Carbogen Amcis BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact Dishman Carbogen Amcis BCG Matrix you'll receive after purchase-no watermarks, no sample content, just the fully formatted, analysis-ready report tailored for strategic clarity and professional use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon Core Commodity Chemicals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCertain basic chemical products in Dishman Carbogen Amcis' portfolio face intense price competition and near-zero market growth, producing mid-2024 EBITDA margins below 5% and ROIC under 3%, so returns are poor.\u003c\/p\u003e\n\u003cp\u003eThese commodities have low market share versus diversified giants (sub-1% global share), as DCA lacks scale and global feedstock integration, limiting pricing power.\u003c\/p\u003e\n\u003cp\u003eBy 2025 these units tie up working capital and capex (~10-15% of group capex), seen as distractions.\u003c\/p\u003e\n\u003cp\u003eDivestment or phased withdrawal is recommended for these low-margin legacy assets to free capital for specialty and CDMO growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnderutilized Legacy Indian Manufacturing Sites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOlder Dishman Carbogen Amcis Indian plants, many built pre-2000, run at sub-50% capacity versus industry \u0026gt;70% for modern CDMOs, yielding low market share in high-potency APIs; FY2024 segment margins reported near break-even and maintenance capex up ~15% year-over-year. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow Margin Bulk Chemical Trading\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe trading of bulk chemicals, once a small revenue tail, now yields negligible strategic value for Dishman Carbogen Amcis' core CDMO (contract development and manufacturing organization) business; FY2024 trading EBIT margin fell below 2% and contributed under 4% of consolidated revenue (~INR 120 crore of INR 3,000 crore). \u003c\/p\u003e\n\u003cp\u003eThis segment sits in a low-growth market (global commodity chemical growth ~1-2% annually) with razor-thin margins and minimal market share, tying up working capital-DSO for trading rose to ~75 days in 2024-capital better used for 30-40% margin pharma services. \u003c\/p\u003e\n\u003cp\u003eThe company is cutting exposure: management reduced trading inventory by ~25% in 2024 and plans further exits, reallocating cash toward high-margin development and biologics capacity expansions slated for 2025. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eObsolete Pharmaceutical Intermediates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eObsolete pharmaceutical intermediates at Dishman Carbogen Amcis have under 5% share in markets shrinking ~6-8% annually as therapy classes shift to biologics and novel small molecules; typical SKU yields \u0026lt;1% gross margin and ties up ~12-18% of working capital in warehousing and compliance overhead.\u003c\/p\u003e\n\u003cp\u003eClearing these cash-trap SKUs frees capacity and reduces annual carrying costs by an estimated 1.2-2.5 million USD, letting R\u0026amp;D and production focus on high-value modern chemistry with \u0026gt;25% EBITDA potential.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow share: \u0026lt;5%\u003c\/li\u003e\n\u003cli\u003eMarket decline: 6-8%\/yr\u003c\/li\u003e\n\u003cli\u003eMargin per SKU: \u0026lt;1%\u003c\/li\u003e\n\u003cli\u003eWC tied: 12-18%\u003c\/li\u003e\n\u003cli\u003ePotential cost save: $1.2-2.5M\/yr\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmall Scale Specialty Segments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn the 2025 BCG matrix for Dishman Carbogen Amcis, niche chemical lines that never scaled are classified as dogs; together they contributed under 4% of group revenue (≈USD 8-12m) and showed EBITDA margins below 5% in FY2024.\u003c\/p\u003e\n\u003cp\u003eThese small units lack durable advantages in a mature CRO\/CDMO market, demand outsized management time, and depress overall ROIC; management is pursuing divestment or closure to refocus on core, higher-margin APIs and biologics services.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRevenue share: \u0026lt;4% (≈USD 8-12m)\u003c\/li\u003e\n\u003cli\u003eEBITDA margin: \u0026lt;5% in FY2024\u003c\/li\u003e\n\u003cli\u003eROIC drag: measurable vs group average (~mid-teens)\u003c\/li\u003e\n\u003cli\u003eLikely action: divestment\/closure in 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow‑return \"Dogs\" (\u0026lt;4% sales) slated for 2025 divestment to fund CDMO\/biologics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs: legacy commodity and niche intermediate lines made \u0026lt;4% of revenue (~USD 8-12m) in FY2024, EBITDA \u0026lt;5%, ROIC \u0026lt;3-5%, tying 12-18% working capital and ~10-15% of group capex; management plans divestment\/closure in 2025 to reallocate cash to 30-40% margin CDMO and biologics growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (FY2024\/2025)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue share\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;4% (≈USD 8-12m)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEBITDA margin\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eROIC\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;3-5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWC tied\u003c\/td\u003e\n\u003ctd\u003e12-18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex share\u003c\/td\u003e\n\u003ctd\u003e10-15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAction\u003c\/td\u003e\n\u003ctd\u003eDivest\/close 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiologics and Biosimilar CDMO Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDishman Carbogen Amcis is entering the biologics and biosimilar CDMO market-a high-growth sector projected at CAGR ~12% to reach ~$300bn by 2030-while holding low current share and needing heavy capex to build GMP biologics suites (typical facility costs $50-150m). \u003c\/p\u003e\n\u003cp\u003eIf DCA leverages existing pharma clients and grows biologics revenue from near-zero, upside could be large: margins and contract values often 2-3x small-molecule work, turning this Question Mark into a Star if adoption accelerates. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCell and Gene Therapy Support Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe emerging cell and gene therapy market grew 28% in 2024 to $18.6B, offering high-growth opportunity for CDMOs with advanced tech; Dishman Carbogen Amcis is in the Question Marks quadrant as it builds early market share in this complex, highly regulated sector.\u003c\/p\u003e\n\u003cp\u003eHigh demands for specialized talent and single-use bioreactors push capex and OPEX up front, causing low initial margins and cash burn-Dishman reported 2024 R\u0026amp;D and capex increases of ~22% vs 2023.\u003c\/p\u003e\n\u003cp\u003eSuccess hinges on quickly securing early-stage contracts-industry data shows winning 3-5 Phase I\/II programs within 24 months typically flips economics-and on scaling expertise to improve utilization and margins. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAI Integrated Drug Discovery Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAI Integrated Drug Discovery Platforms sit in the Question Marks quadrant: high 2025 market growth (AI in drug discovery CAGR ~40% to 2030) but Dishman Carbogen Amcis holds low share (\u0026lt;5% of digital services revenue), so short-term losses from heavy R\u0026amp;D capex (estimated $10-25m 2024-25) are likely.\u003c\/p\u003e\n\u003cp\u003eThese platforms can attract tech-forward biotech partners-AI deals raised $16.4bn in 2024-so management must choose between aggressive investment to capture share or partnering with established AI firms to limit cash burn and speed commercialization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmerging Market Custom Synthesis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eExpanding Dishman Carbogen Amcis custom synthesis into high-growth emerging markets offers upside but current market share is low versus strong local players; Southeast Asia and Latin America pharma R\u0026amp;D grew ~8-12% CAGR 2019-2024, driving demand.\u003c\/p\u003e\n\u003cp\u003eTurning these regions into BCG Question Marks requires heavy capex for local compliance ( GMP audits, regulatory registrations often $2-5M per country) and BD to capture share and become Stars.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow current share vs locals\u003c\/li\u003e\n\u003cli\u003eSE Asia\/LatAm R\u0026amp;D +8-12% CAGR 2019-24\u003c\/li\u003e\n\u003cli\u003eCompliance spend ~$2-5M\/country\u003c\/li\u003e\n\u003cli\u003eHigh upside if share rises \u0026gt;10-15% over 3-5 yrs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContinuous Flow Manufacturing Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eContinuous flow chemistry (continuous flow manufacturing services) offers 30-60% lower reaction times and up to 40% smaller footprint vs batch; Dishman Carbogen Amcis is building capabilities but held under 5% of the specialized contract manufacturing market in 2024.\u003c\/p\u003e\n\u003cp\u003eAdoption needs client mindset change and $2-10m per plant in specialized reactors; if Dishman proves a payback under 24 months to top 10 pharma buyers, share could jump fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEfficiency: 30-60% faster reactions\u003c\/li\u003e\n\u003cli\u003eCapex: $2-10m per facility\u003c\/li\u003e\n\u003cli\u003eCurrent share: \u0026lt;5% (2024)\u003c\/li\u003e\n\u003cli\u003eKey win: 24-month payback to major clients\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDishman Carbogen Amcis: Targeting biologics, cell\/gene, AI, emerging markets, continuous flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDishman Carbogen Amcis: multiple Question Marks-biologics CDMO (CAGR ~12% to ~$300B by 2030; facility $50-150M), cell\/gene therapy (2024 $18.6B; +28% YoY), AI drug discovery (AI drug discovery CAGR ~40% to 2030; DCA \u0026lt;5% share), emerging markets (SE Asia\/LatAm R\u0026amp;D +8-12% CAGR; compliance $2-5M\/country), continuous flow (\u0026lt;5% share; $2-10M capex).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eOpportunity\u003c\/th\u003e\n\u003cth\u003e2024\/25 stat\u003c\/th\u003e\n\u003cth\u003eCapex\u003c\/th\u003e\n\u003cth\u003eKey trigger\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiologics CDMO\u003c\/td\u003e\n\u003ctd\u003eCAGR ~12% to $300B (2030)\u003c\/td\u003e\n\u003ctd\u003e$50-150M\u003c\/td\u003e\n\u003ctd\u003eWin 3-5 programs\/24m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCell \u0026amp; gene\u003c\/td\u003e\n\u003ctd\u003e$18.6B (2024; +28%)\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eAdvanced tech wins\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI discovery\u003c\/td\u003e\n\u003ctd\u003eCAGR ~40% to 2030; DCA \u0026lt;5%\u003c\/td\u003e\n\u003ctd\u003e$10-25M\u003c\/td\u003e\n\u003ctd\u003ePartnerships or fast commercialization\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmerging markets\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D +8-12% (2019-24)\u003c\/td\u003e\n\u003ctd\u003e$2-5M\/country\u003c\/td\u003e\n\u003ctd\u003eCapture \u0026gt;10-15% share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContinuous flow\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5% share (2024)\u003c\/td\u003e\n\u003ctd\u003e$2-10M\u003c\/td\u003e\n\u003ctd\u003e24m payback to top clients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"BCG Matrix","offers":[{"title":"Default Title","offer_id":44509030809683,"sku":"dishmangroup-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0709\/3102\/1907\/files\/dishmangroup-bcg-matrix.webp?v=1776716640","url":"https:\/\/bcgmatrixtemplate.com\/products\/dishmangroup-bcg-matrix","provider":"BCG Matrix","version":"1.0","type":"link"}